阿卡波糖
化学
噻唑
对接(动物)
IC50型
立体化学
糖尿病
体外
组合化学
香豆素
酶
药品
酶动力学
配体(生物化学)
药理学
生物化学
活动站点
受体
有机化学
医学
护理部
内分泌学
作者
Qurat Ul Ain,Aamer Saeed,Ajmal Khan,Atteeque Ahmed,Saeed Ullah,Sobia Ahsan Halim,M. Nurul Irfan,Arfa Tehzeeb,Hesham R. El‐Seedi,Abdullatif Bin Muhsinah,Ahmed Al‐Harrasi
标识
DOI:10.1016/j.bioorg.2022.106302
摘要
The current studies mainly demonstrate the coumarin based azomethine-clubbed thiazoles synthesis and their in-vitro evaluation for the first time against α-glucosidase. Due to the catalytic role of α-glucosidase, it has become a precise target for the treatment of type diabetes mellitus (T2DM). The high rate of prevalence of diabetes and its associated health related problems led us to scrutinize the anti-diabetic capability of the synthesized thiazole derivatives (6a-6k). The anticipated structures of prepared compounds were confirmed through FT-IR and NMR spectroscopic methods. All the compounds showed several times potent activity than the standard drug, acarbose (IC50 = 873.34 ± 1.67 µM) against α-glucosidase with IC50 values in range of 0.87 ± 0.02-322.61 ± 1.14 µM. The compound 6k displayed the highest anti-diabetic activity (IC50 = 1.88 ± 0.03 µM). Kinetic study revealed that these are competitive inhibitors for α-glucosidase. The mode of binding of the synthesized molecules were further evaluated by molecular docking, which reflects the importance of azomethine group in protein-ligand interaction. The docking scores are complementary with the IC50 values of compounds while the interaction pattern of the compounds clearly demonstrates their structure-activity relationship. Current study reported medicinal importance of thiazole derivative as future drug candidates for the management of Type 2 Diabetes Mellitus (T2DM).
科研通智能强力驱动
Strongly Powered by AbleSci AI